The GSK3 hypothesis of Alzheimer’s disease

Abstract

J. Neurochem. (2008) 104, 1433–1439. Glycogen synthase kinase 3 (GSK3) is a constitutively active, proline‐directed serine/threonine kinase that plays a part in a number of physiological processes ranging from glycogen metabolism to gene transcription. GSK3 also plays a pivotal and central role in the pathogenesis of both sporadic and familial forms of Alzheimer’s disease (AD), an observation that has led us to coin the ‘GSK3 hypothesis of AD’. According to this hypothesis, over‐activity of GSK3 accounts for memory impairment, tau hyper‐phosphorylation, increased β‐amyloid production and local plaque‐associated microglial‐mediated inflammatory responses; all of which are hallmark characteristics of AD. If our ‘GSK3 hypothesis of AD’ is substantiated and GSK3 is indeed a causal mediator of AD then inhibitors of GSK3 would provide a novel avenue for therapeutic intervention in this devastating disorder.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 75

1. 1.

   Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, az-Nido J. Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 1999;453:260-264.

   Not in our library10.1016/s0014-5793(99)00685-7

2. 2.

   Anderton BH, Betts J, Blackstock WP, et al. Sites of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp. 2001;67:73-80.

   Not in our library10.1042/bss0670073

3. 3.

   Asuni AA, Hooper C, Reynolds CH, Lovestone S, Anderton BH, Killick R. GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur. J. Neurosci. 2006;24:3387-3392.

   Not in our library10.1111/j.1460-9568.2006.05243.x

4. 4.

   Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis NK. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 2004;23:2586-2596.

   Not in our library10.1038/sj.emboj.7600251

5. 5.

   Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, Lee CM. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci USA. 2000;97:11074-11079.

   Not in our library10.1073/pnas.190297597

6. 6.

   Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem. Soc. Trans. 2005;33:1041-1044.

   Not in our library10.1042/bst0331041

7. 7.

   Bijur GN, Jope RS. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J. Biol. Chem. 2001;276:37436-37442.

   Not in our library10.1074/jbc.m105725200

8. 8.

   Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. PNAS. 2004;101:2173-2178.

   Not in our library10.1073/pnas.0308512100

9. 9.

   Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, Octave JN, Pradier L, Touchet N, Tremp G. Neurofibrillary tangles and tau phosphorylation. Biochem. Soc. Symp. 2001;0:81-88.

   Not in our library10.1042/bss0670081

10. 10.

    Bullock BP, Habener JF. Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge. Biochemistry. 1998;37:3795-3809.

    Not in our library10.1021/bi970982t

11. 11.

    Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci. 2004;24:6021-6027.

    Not in our library10.1523/jneurosci.1381-04.2004

12. 12.

    Chen J, Park CS, Tang SJ. Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J. Biol. Chem. 2006;281:11910-11916.

    Not in our library10.1074/jbc.m511920200

13. 13.

    Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J. Biol. Chem. 2003;278:187-193.

    Not in our library10.1074/jbc.m206236200

14. 14.

    Christie RH, Freeman M, Hyman BT. Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am. J. Pathol. 1996;148:399-403.

    Not in our library

15. 15.

    Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN, Sutherland C. GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J. Biol. Chem. 2004;279:50176-50180.

    Not in our library10.1074/jbc.c400412200

16. 16.

    Dale TC. Signal transduction by the Wnt family of ligands. Biochem. J. 1998;329 (Pt 2):209-223.

    Not in our library10.1042/bj3290209

17. 17.

    De Ferrari GV, Papassotiropoulos A, Biechele T, et al. Common genetic variation within the low-density lipoprotein receptor-related Protein 6 and late-onset Alzheimer's disease. PNAS. 2007;104:9434-9439.

    Not in our library10.1073/pnas.0603523104

18. 18.

    Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003;116:1175-1186.

    Not in our library10.1242/jcs.00384

19. 19.

    Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev. Cell. 2007;12:957-971.

    Not in our library10.1016/j.devcel.2007.04.001

20. 20.

    Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 2006;99:1445-1455.

    Not in our library10.1111/j.1471-4159.2006.04139.x

21. 21.

    Hamilton G, Proitsi P, Jehu L, Morgan A, Williams J, O'Donovan MC, Owen MJ, Powell JF, Lovestone S. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am. J Med Genet B Neuropsychiatr. Genet. 2007;144:508-516.

    Not in our library10.1002/ajmg.b.30503

22. 22.

    Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 1992;147:58-62.

    Not in our library10.1016/0304-3940(92)90774-2

23. 23.

    Hansen TO, Rehfeld JF, Nielsen FC. GSK-3beta reduces cAMP-induced cholecystokinin gene expression by inhibiting CREB binding. Neuroreport. 2004;15:841-845.

    Not in our library10.1097/00001756-200404090-00021

24. 24.

    Hardy J. A hundred years of Alzheimer's disease research. Neuron. 2006;52:3-13.

    Not in our library10.1016/j.neuron.2006.09.016

25. 25.

    Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 2002;83:1529-1533.

    Not in our library10.1046/j.1471-4159.2002.01269.x

26. 26.

    Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000;406:86-90.

    Not in our library10.1038/35017574

27. 27.

    Hooper C, Markevich V, Plattner F, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur. J. Neurosci. 2007;25:81-86.

    Not in our library10.1111/j.1460-9568.2006.05245.x

28. 28.

    Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, Saitoh Y, Ishiguro K, Hoshino T, Imahori K. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc. Natl. Acad. Sci USA. 1996;93:2719-2723.

    Not in our library10.1073/pnas.93.7.2719

29. 29.

    Huelsken J, Behrens J. The Wnt signalling pathway. J. Cell Sci. 2002;115:3977-3978.

    Not in our library10.1242/jcs.00089

30. 30.

    Hye A, Kerr F, Archer N, Foy C, Poppe M, Brown R, Hamilton G, Powell J, Anderton B, Lovestone S. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci. Lett. 2005;373:1-4.

    Not in our library10.1016/j.neulet.2004.10.031

31. 31.

    Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem. (Tokyo). 1997;121:179-188.

    Not in our library

32. 32.

    Ishiguro K, Omori A, Takamatsu M, Sato K, Arioka M, Uchida T, Imahori K. Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett. 1992;148:202-206.

    Not in our library10.1016/0304-3940(92)90839-y

33. 33.

    Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 2007;32:577-595.

    Not in our library10.1007/s11064-006-9128-5

34. 34.

    Joshi SN, Crutcher KA. Rat microglia exhibit increased density on Alzheimer's plaques in vitro. Exp. Neurol. 1998;149:42-50.

    Not in our library10.1006/exnr.1997.6678

35. 35.

    Koivisto L, Hakkinen L, Matsumoto K, McCulloch CA, Yamada KM, Larjava H. Glycogen synthase kinase-3 regulates cytoskeleton and translocation of Rac1 in long cellular extensions of human keratinocytes. Exp. Cell Res. 2004;293:68-80.

    Not in our library10.1016/j.yexcr.2003.09.026

36. 36.

    Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. Appl. Neurobiol. 2007;33:43-55.

    Not in our library10.1111/j.1365-2990.2006.00795.x

37. 37.

    Lesort M, Jope RS, Johnson GV. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem. 1999;72:576-584.

    Not in our library10.1046/j.1471-4159.1999.0720576.x

38. 38.

    Lizcano JM, Alessi DR. The insulin signalling pathway. Curr. Biol. 2002;12:R236-R238.

    Not in our library10.1016/s0960-9822(02)00777-7

39. 39.

    Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 1994;4:1077-1086.

    Not in our library10.1016/s0960-9822(00)00246-3

40. 40.

    Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20:27-39.

    Not in our library10.1093/emboj/20.1.27

Cited by papers we hold 24

• Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies · 2024
  No notice
• WNT-β Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective · 2023
  No notice
• The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review · 2022
  No notice
• Meridianins Rescue Cognitive Deficits, Spine Density and Neuroinflammation in the 5xFAD Model of Alzheimer’s Disease · 2022
  Not checked
• The Continuing Evolution of Insulin-like Growth Factor Signaling [version 1; peer review: 4 approved] · 2020
  Not checked
• GSK3β and Tau Protein in Alzheimer’s Disease and Epilepsy · 2020
  No notice
• Neuroinflammation and Neurogenesis in Alzheimer’s Disease and Potential Therapeutic Approaches · 2020
  No notice
• Endoplasmic Reticulum Stress and Unfolded Protein Response in Neurodegenerative Diseases · 2020
  No notice
• Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development · 2019
  No notice
• Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease · 2019
  No notice
• Brain somatic mutations observed in Alzheimer’s disease associated with aging and dysregulation of tau phosphorylation · 2019
  No notice
• S100 Proteins in Alzheimer’s Disease · 2019
  No notice
• WNT Signaling in Disease · 2019
  No notice
• An Overview on the Clinical Development of Tau-Based Therapeutics · 2018
  No notice
• MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways · 2018
  No notice
• Molecular Mechanisms for Herpes Simplex Virus Type 1 Pathogenesis in Alzheimer’s Disease · 2018
  No notice
• Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation · 2017
  No notice
• Multifaceted Roles of GSK‐3 in Cancer and Autophagy‐Related Diseases · 2017
  No notice
• ER–mitochondria associations are regulated by the VAPB–PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43 · 2014
  No notice
• Protein phosphorylation in neurodegeneration: friend or foe? · 2014
  No notice

and 4 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.